Previous 10 | Next 10 |
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translatio...
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A. As previously announced, the transfer includes the entire Jysel...
2024-01-08 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-04 16:09:09 ET More on Galapagos Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos signs development deal with BridGene Galapagos to transfer Jyseleca business to Alfasigma For further details see: Galapagos enters into st...
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the San Francisco area Agreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the Boston are...
2024-01-03 16:39:19 ET More on Galapagos Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos NV 2023 Q3 - Results - Earnings Call Presentation Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript Galapagos to transfer Jyseleca business ...
Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and development with BridGene’s innovative discover...
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets PR Newswire BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan....
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
2024-01-02 02:37:43 ET More on Galapagos: Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma For further details see: Galapagos to transfe...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...